Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients
NCT02574091Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icotinib in psoriasis (8 cohorts), sponsored by Betta Pharmaceuticals. Primary endpoint: Adverse events at 14 days. Started Nov 2015; status: completed.
02
Drugs
icotinib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02574091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574091.